Bayer's KERENDIA Poised to Disrupt Kidney Disease Market After Landmark Trial

WHIPPANY, NJ – June 05, 2026 – In a significant development for both patients and the pharmaceutical industry, Bayer announced overwhelmingly positive results from a major clinical trial for its drug KERENDIA® (finerenone). The findings, presented as a late-breaking presentation at the 63rd European Renal Association (ERA) Congress and simultaneously published in the prestigious New England Journal of Medicine, demonstrate the drug's ability to treat a massive, underserved segment of the population: adults with chronic kidney disease (CKD) not caused by diabetes.

The results from the Phase III FIND-CKD trial signal a potential paradigm shift in how millions of patients are treated, moving beyond symptom management to actively slowing disease progression and protecting against dire cardiovascular outcomes. For Bayer, this scientific victory represents a calculated strategic success, positioning the company to dominate a new frontier in the multi-billion-dollar renal care market.

A New Hope for a Vast, Underserved Population

Chronic kidney disease is a silent global epidemic, affecting an estimated 850 million people and ranking as the ninth leading cause of death. While its link to diabetes is well-known, a startling and often-overlooked fact is that 50-70% of CKD cases arise from other causes, such as hypertension or inflammation. This vast population has long faced a scarcity of targeted treatment options.

“Chronic kidney disease is underrecognized and underdiagnosed in the United States, leaving many patients at risk for kidney failure and cardiovascular events,” said Dr. Rajiv Agarwal, a member of the study’s Executive Committee, in a statement. “Despite available treatments, there remains a critical unmet need.”

The FIND-CKD trial was designed to address this exact gap. The study showed that KERENDIA met its primary goal by significantly slowing the rate of kidney function decline over time. Specifically, the mean annual rate of decline was -3.3 mL/min/1.73 m² for patients on KERENDIA, compared to -4.0 mL/min/1.73 m² for the placebo group. While the numbers seem small, this 0.7 mL/min difference per year represents a meaningful preservation of organ function, potentially delaying the need for dialysis by years.

Perhaps more critically, the drug also delivered a powerful one-two punch by protecting the heart. The trial’s secondary endpoint—a composite of kidney failure, a sustained 57% or greater drop in kidney function, hospitalization for heart failure, or cardiovascular death—was reduced by a statistically significant 23% in the KERENDIA group compared to placebo. For patients whose lives are defined by the dual threat of kidney failure and heart disease, this is a monumental development.

Bayer's Strategic Play in a Multi-Billion Dollar Market

Beyond the clinical breakthrough, the FIND-CKD results represent a masterful strategic move by Bayer. The German pharmaceutical giant has been methodically building a cardiovascular and renal franchise, and KERENDIA is its centerpiece. Having already secured approval for CKD associated with type 2 diabetes, this expansion into the much larger non-diabetic population is set to transform the drug into a blockbuster therapy.

Financial analysts are already taking note. Following the data release, some have upgraded peak sales forecasts for KERENDIA to over €3 billion, citing the massive addressable market of non-diabetic patients. This success solidifies Bayer’s position in a highly competitive space currently dominated by SGLT2 inhibitors like AstraZeneca's Farxiga and Boehringer Ingelheim/Eli Lilly's Jardiance. However, KERENDIA's distinct mechanism of action as a non-steroidal mineralocorticoid receptor antagonist (nsMRA) means it doesn't just compete—it offers a complementary or alternative pathway, targeting inflammation and fibrosis, which are key drivers of disease progression that other drugs don't fully address.

This is not an accidental success but the culmination of a long-term vision. Bayer's comprehensive “FINEOVATE” clinical trial program, which includes 12 Phase III studies, demonstrates a deep and sustained investment in tackling the interconnectedness of heart and kidney diseases.

“The FIND-CKD data mark another key milestone reinforcing KERENDIA’s potential to reduce the risk of kidney and cardiovascular events,” said Carolina Aldworth, M.D., MSc, Executive Medical Director at Bayer. The company’s commitment underscores a strategy focused on owning complex, chronic disease markets where true innovation can command both clinical loyalty and significant financial returns.

The Clinical Nuances: Balancing Efficacy with Risk

At the heart of KERENDIA's success is its novel mechanism. As a selective nsMRA, it potently blocks the overactivation of receptors in the heart and kidneys that lead to harmful inflammation and fibrosis—the scarring that ultimately destroys organ function. This targeted approach is what sets it apart from older, steroidal MRAs, which carried a higher risk of side effects.

However, no powerful drug comes without risks. The primary side effect of concern is hyperkalemia, or elevated potassium levels in the blood. In the FIND-CKD trial, hyperkalemia was observed more frequently with KERENDIA (17%) compared to placebo (13.3%).

Yet, the data suggests this risk is highly manageable. The rate of serious hyperkalemia events was less than 1% in both groups, and less than 2% of patients on KERENDIA had to discontinue the study due to it. For clinicians, this indicates that with proper patient selection and routine monitoring of potassium levels—a standard practice in nephrology—the profound benefits of the drug can be safely realized. The favorable risk-benefit profile is a critical factor that will likely accelerate adoption once approved.

The Path to Patients: Navigating the Regulatory Gauntlet

The journey from trial results to patient access now enters its final, crucial stage: regulatory review. Bayer has confirmed it will begin discussions with health authorities worldwide, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), to seek a label expansion for KERENDIA.

Given the strength of the data and the significant unmet need, the company may be eligible for a Priority Review from the FDA, which could shorten the approval timeline to as little as six months after submission. Pharmaceutical industry experts anticipate that regulatory filings could occur before the end of the year, potentially putting the drug in the hands of non-diabetic CKD patients in the U.S. by late 2027 or early 2028.

With a robust data package demonstrating both kidney and heart protection, Bayer now turns its attention to the regulatory bodies that hold the key to unlocking KERENDIA's potential for one of medicine's most widespread and underserved patient populations.